Pentokey Organy (524210)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Positive book value of ₹16.46 per share provides some asset backing, though price is well above it.
• Trailing earnings are positive (P/E exists), indicating the company is not yet in an annual loss-making zone.
• Sales growth of 0.00% suggests no dramatic revenue collapse, offering a base for potential stabilization.
• The stock trades within a 52-week range of ₹28.49 to ₹57.00, showing market interest and liquidity.

Concerns

• Profit growth is -825.00%, showing severe earnings deterioration.
• Latest quarter sales are -₹2 crore and net profit -₹0 crore, pointing to operational distress.
• ROE of 4.15% and ROCE of 2.67% are far below acceptable return thresholds.
• Piotroski F-Score of 3/9 indicates weak financial health, and P/E of 64.31 is expensive for stagnant sales.

AI Analysis

Friends, let me walk you through Pentokey Organy. A market cap of ₹31 crore, a commodity chemical maker with no discernible moat. Sales growth is 0.00%, so the company is running in place. Profit growth is -825.00%, meaning whatever earnings existed are evaporating. Yes, there is a positive trailing P/E of 64.31, but that price implies you're paying 64 years of current earnings for a business whose latest quarter shows sales of -₹2 crore and net profit of -₹0 crore. ROE of 4.15% and ROCE of 2.67% are far below what I'd accept; a simple bank fixed deposit offers better with no business risk. Book value per share is ₹16.46, so there is some asset support, but at ₹49.25 you're paying 2.99 times book for a decelerating operation. The Piotroski F-Score of 3/9 is a flashing red light. No dividend, no growth, and an industry that gives no pricing power—this is the opposite of my 'wonderful company at a fair price' test. Some will call it a value play because the share price fell from ₹57 to ₹28 and has bounced to ₹49. But value investing is not bottom-fishing in a stalled business. Graham would remind us that the margin of safety lies in assets and earnings power, not in a ticker chart. Here the earnings power is negative and the asset backing is thin relative to price. Unless management can demonstrate a genuine turnaround—positive quarterly sales, expanding margins, higher ROCE—the stock remains a pass. I'd rather miss an uncertain recovery than risk permanent capital. In the words of Buffett: 'It's better to hang out with people better than you. Pick associates whose behavior is better than yours and you'll drift in that direction.' Pentokey's behavior is poor. I'll stand aside.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer